Posted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin condition was spread all over his body, his arms and legs covered with a deep-seated itch that oozed clear liquid.
No solution seemed permanent. Tang changed his diet, he prioritised sleep to reduce stress, he took steroids that relieved the itch but left him hopped up on drugs with the promise of a wicked skin flare up when he eventually stopped taking them.
Out of options, Tang’s doctor recommended him to a dermatologist conducting a clinical trial for dupilumab, a biologic used internationally to treat those who have moderate to severe eczema.
